OA
NRIX icon

Oracle Alpha’s Nurix Therapeutics NRIX Stock Holding History

Oracle Alpha’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$170K Sell
11,538
-5,896
-34% -$63.4K 0.3% 152
2023
Q4 		$180K Buy
+17,434
New +$119K 0.23% 200

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Oracle Alpha's NRIX Position: Q1 2024 in Review

Oracle Alpha reduced its Nurix Therapeutics (NRIX) stake by 34% in Q1 2024, selling an estimated $63.4K and leaving 11,538 shares worth $170K. The position accounts for 0.3% of the portfolio, ranked #152.

Oracle Alpha first reported a position in NRIX in Q4 2023 and has held it in 2 quarters since. The position peaked at $180K in Q4 2023. 139 funds tracked by Wall St. Rank hold NRIX as of Q1 2024.

  • Oracle Alpha held 11,538 shares of Nurix Therapeutics worth $170K as of Q1 2024.
  • Oracle Alpha sold 5,896 Nurix Therapeutics shares in Q1 2024, an estimated $63.4K.
  • Nurix Therapeutics made up 0.3% of Oracle Alpha's portfolio in Q1 2024, its #152 holding.
  • Oracle Alpha first reported a position in Nurix Therapeutics in Q4 2023 and has held it in 2 quarters since.
  • Oracle Alpha's Nurix Therapeutics position peaked at $180K in Q4 2023.
  • 139 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2024.

Based on Oracle Alpha's 13F filing for Q1 2024, filed 15 May 2024.